髙橋和久 医師 たかはしかずひさ

髙橋和久医師は、呼吸器内科一般を専門とし、肺がん、中皮腫だけでなく、アレルギー疾患、感染症、間質性肺炎など幅広い呼吸器系の疾患のスペシャリストである。がんの中で最も死亡率が高く治りにくいとされる肺がん治療にあえて挑みたいと肺がんの治療医師を志したと言う。
また、髙橋医師は、日本で初めて開設した最も古い歴史を有する呼吸器内科専門教室で2005年8月から主任教授として教室の運営にもあたっており、教育や育成、研究に力を入れている。2019年からは順天堂大学医学部附属順天堂医院院長を併任し、病院運営にも関わっている。中国の複数の大学の教授も併任している。
主な研究テーマには、抗がん剤や分子標的薬など、薬剤の耐性機序の解明と克服。薬が効かなくなった患者さんに効く薬を生む「創薬」をめざす。

原則として他の医療機関からの紹介状(診療情報提供書)が必要。紹介状がない場合は、初診時選定療養費として別途費用が必要となる。

1960年　東京都生まれ
1985年　順天堂大学医学部卒業
1994年～1997年　米国ハーバード大学医学部附属マサチューセッツ総合病院 腫瘍外科学留学 ポスドク
2003年　順天堂大学医学部呼吸器内科学講座助教授、順天堂大学大学院医学研究科呼吸器内科学助教授併任
2005年　順天堂大学医学部呼吸器内科学講座教授、順天堂大学大学院医学研究科呼吸器内科学教授併任
2014年　順天堂大学医学部附属順天堂医院　副院長
2019年　順天堂大学医学部附属順天堂医院　院長
2019年　西安交通大学第二附属医院（西北医院）特別栄誉教授
2020年　北京大学客員教授
2021年　中国医科大学客員教授

日本内科学会(評議員2012.4.14～/日本内科学会雑誌主任編集長2021.4～)
日本呼吸器学会(理事長 2024.4.1～、常務理事 2018.4.26～/理事2008.6.14～/代議員、第63回日本呼吸器学会学術講演会会長(2023年))
日本肺癌学会(常任理事、理事2012.11.10～/評議員/保険委員会委員長/第66回日本肺癌学会学術集会会長(2025年))
日本癌学会
日本臨床腫瘍学会(評議員)
日本サルコイドーシス/肉芽腫性疾患学会(理事/評議員)
日本呼吸器内視鏡学会(代議員/気管支鏡専門医制度委員会委員)
日本呼吸器内視鏡学会関東部会(幹事)
日本肺癌学会関東部会(幹事)
日本老年医学会(代議員)
日本呼吸ケア・リハビリテーション学会(代議員)
日本免疫学会
日本アレルギー学会
日本病理学会
ATS(米国胸部学会)会員
ASCO(米国臨床腫瘍学会)正会員
APTA（アジア太平洋胸部疾患協会）代表理事
APSR(Asia Pacific Society of Respirology) 理事
IASLC(国際肺癌学会)会員

【受賞歴】
2002年　順天堂大学医学部同窓会学術奨励賞
2014年　APSR Harasawa Research Award
2017年　東京都医師会功労賞
2021年　日本医師会優功賞

世界で一番やさしい　肺がん(知ってなおすシリーズ)　高橋和久著　発行/エクスナレッジ
呼吸器内科　診療マニュアル　高橋和久、熱田了編集　日本医学館
講義録　腫瘍学　高橋和久編集　メジカルビュー社
EBMを活かす呼吸器診療　高橋和久、児玉裕三編集　メジカルビュー社
がんサポート　肺がん特集&リハビリテーション2015年9月号　エビデンス社
など多数

【論文】2022年1月-2023年9月までの英文論文のみ
1.Mimori T, Shukuya T, Ko R, Okuma Y, Koizumi T, Imai H, Takiguchi Y, Miyauchi E, Kagamu H, Sugiyama T, Azuma K, Namba Y, Yamasaki M, Tanaka H, Takashima Y, Soda S, Ishimoto O, Koyama N, Kobayashi K, Takahashi K. Clinical Significance of Tumor Markers for Advanced Thymic Carcinoma: A Retrospective Analysis from the NEJ023 Study. Cancers (Basel). 14(2):331, 2022 Jan

2.Tada H, Mitsudomi T, Misumi T, Sugio K, Tsuboi M, Okamoto I, Iwamoto Y, Sakakura N, Sugawara S, Atagi S, Takahashi T, Hayashi H, Okada M, Inokawa H, Yoshioka H, Takahashi K, Higashiyama M, Yoshino I, Nakagawa K; West Japan Oncology Group. Randomized Phase III Study of Gefitinib Versus Cisplatin Plus Vinorelbine for Patients With Resected Stage II-IIIA Non-Small-Cell Lung Cancer With EGFR Mutation (IMPACT). J Clin Oncol. 40(3):231-241, 2022 Jan

3.Wirawan A, Tajima K, Takahashi F, Mitsuishi Y, Winardi W, Hidayat M, Hayakawa D, Matsumoto N, Izumi K, Asao T, Ko R, Shimada N, Takamochi K, Suzuki K, Abe M, Hino O, Sekido Y, Takahashi K. A Novel Therapeutic Strategy Targeting the Mesenchymal Phenotype of Malignant Pleural Mesothelioma By Suppressing LSD1. Mol Cancer Res. 20(1):127-138, 2022 Jan

4.Jo H, Yoshida T, Horinouchi H, Yagishita S, Matsumoto Y, Shinno Y, Okuma Y, Goto Y, Yamamoto N, Takahashi K, Motoi N, Ohe Y. Prognostic significance of cachexia in advanced non-small cell lung cancer patients treated with pembrolizumab. Cancer Immunol Immunother. 71(2):387-398, 2022 Feb

5.Jo H, Yagishita S, Hayashi Y, Ryu S, Suzuki M, Kohsaka S, Ueno T, Matsumoto Y, Horinouchi H, Ohe Y, Watanabe SI, Motoi N, Yatabe Y, Mano H, Takahashi K, Hamada A. Comparative Study on the Efficacy and Exposure of Molecular Target Agents in Non-small Cell Lung Cancer PDX Models with Driver Genetic Alterations. Mol Cancer Ther. 21(2):359-370, 2022 Feb

6.Miyawaki T, Naito T, Yabe M, Kodama H, Nishioka N, Miyawaki E, Mamesaya N, Kobayashi H, Omori S, Wakuda K, Ono A, Kenmotsu H, Murakami H, Mori K, Harada H, Takahashi K, Takahashi T. Impact of weight loss on treatment with PD-1/PD-L1 inhibitors plus chemotherapy in advanced non-small-cell lung cancer. Support Care Cancer. Support Care Cancer. 30(2):1633-1641, 2022 Feb

7.Enomoto K, Eguchi Y, Sato T, Norimoto M, Inoue M, Watanabe A, Sakai T, Yoneyama M, Aoki Y, Orita S, Narita M, Inage K, Shiga Y, Umimura T, Sato M, Suzuki M, Takaoka H, Mizuki N, Kim G, Hozumi T, Hirosawa N, Furuya T, Maki S, Nakamura J, Hagiwara S, Koda M, Akazawa T, Takahashi H, Takahashi K, Ohtori S. Usefulness of Simultaneous Magnetic Resonance Neurography and Apparent T2 Mapping for the Diagnosis of Cervical Radiculopathy. Asian Spine J. 16(1):47-55, 2022 Feb

8.Miyawaki E, Kenmotsu H, Shintani Y, Sekine I, Shukuya T, Takayama K, Inoue A, Okamoto I, Kiura K, Takahashi K, Yamamoto N, Kawaguchi T, Miyaoka E, Yoshino I, Date H. Efficacy of platinum agents for stage III non-small-cell lung cancer following platinum-based chemoradiotherapy: a retrospective study. BMC Cancer. 22(1):342, 2022 Mar

9.Shimamura SS, Shukuya T, Asao T, Hayakawa D, Kurokawa K, Xu S, Miura K, Mitsuishi Y, Tajima K, Shibayama R, Shimada N, Takahashi F, Takahashi K. Survival past five years with advanced, EGFR-mutated or ALK-rearranged non-small cell lung cancer-is there a "tail plateau" in the survival curve of these patients? BMC Cancer. 22(1):323, 2022 Mar

10.Ueda S, Ito J, Harada N, Harada S, Sasano H, Sandhu Y, Tanabe Y, Abe S, Shiota S, Kodama Y, Nagaoka T, Makino F, Chiba A, Akiba H, Atsuta R, Miyake S, Takahashi K. Effect of Japanese Cedar Pollen Sublingual Immunotherapy on Asthma Patients with Seasonal Allergic Rhinitis Caused by Japanese Cedar Pollen. Biomolecules. 12(4):518, 2022 Mar

11.Xu S, Shukuya T, Tamura J, Shimamura S, Kurokawa K, Miura K, Miyawaki T, Hayakawa D, Asao T, Yamamoto K, Takahashi K. Heterogeneous Outcomes of Immune Checkpoint Inhibitor Rechallenge in Patients With NSCLC: A Systematic Review and Meta-Analysis. JTO Clin Res Rep. 3(4):100309, 2022 Mar

12.Nakamura K, Nakayama H, Sasaki S, Takahashi K, Iwabuchi K. Mycobacterium avium-intracellulare complex promote release of pro-inflammatory enzymes matrix metalloproteinases by inducing neutrophil extracellular trap formation. Sci Rep. 12(1):5181, 2022 Apr

13.Yan Y, Naito T, Tabe Y, Ito K, Nojiri S, Deshpande GA, Seyama K, Takahashi K. Increased delta variant SARS-CoV-2 infections in a highly vaccinated medical center in Japan. Vaccine. 40(23):3103-3108, 2022 May

14.Nitta NA, Sato T, Komura M, Yoshikawa H, Suzuki Y, Mitsui A, Kuwasaki E, Takahashi F, Kodama Y, Seyama K, Takahashi K. Exposure to the heated tobacco product IQOS generates apoptosis-mediated pulmonary emphysema in murine lungs. Am J Physiol Lung Cell Mol Physiol. 322(5):L699-L711, 2022 May

15.Igawa G, Ai T, Yamamoto T, Ito K, Nojiri S, Saito K, Wakita M, Fukuda H, Hori S, Misawa S, Miida T, Seyama K, Takahashi K, Tabe Y, Naito T. Antibody response and seroprevalence in healthcare workers after the BNT162b2 vaccination in a University Hospital at Tokyo. Sci Rep. 12(1):8707, 2022 May

16.Torasawa M, Yoshida T, Yagishita S, Shimoda Y, Shirasawa M, Matsumoto Y, Masuda K, Shinno Y, Okuma Y, Goto Y, Horinouchi H, Yamamoto N, Takahashi K, Ohe Y. Nivolumab versus pembrolizumab in previously-treated advanced non-small cell lung cancer patients: A propensity-matched real-world analysis. Lung Cancer. 167:49-57, 2022 May

17.Tsuchiya K, Hosaka Y, Takahashi T, Chonan M, Makita Y, Katayama I, Ai T, Idei M, Horiuchi Y, Yamatani K, Wakita M, Misawa S, Okuzawa A, Miida T, Naito T, Takahashi K, Tabe Y. Meals and Room Temperature Storage do not Significantly Affect Feasibility of Direct RT-PCR Tests for SARS-CoV-2 Using Saliva. Clin Lab. 68(6) doi: 10.7754/Clin.Lab.2021.210451, 2022 Jun

18.Nanjo Y, Okuma T, Kuroda Y, Hayakawa E, Shibayama K, Akimoto T, Murashima R, Kanamori K, Tsutsumi T, Suzuki Y, Namba Y, Makino F, Nagashima O, Sasaki S, Takahashi K. Multiple Types of Taste Disorders among Patients with COVID-19. Intern Med. 61(14):2127-2134, 2022 Jul

19.Miyawaki T, Naito T, Doshita K, Kodama H, Mori M, Nishioka N, Iida Y, Miyawaki E, Mamesaya N, Kobayashi H, Omori S, Ko R, Wakuda K, Ono A, Kenmotsu H, Murakami H, Mori K, Harada H, Endo M, Takahashi K, Takahashi T. Predicting the efficacy of first-line immunotherapy by combining cancer cachexia and tumor burden in advanced non-small cell lung cancer. Thorac Cancer. 13(14):2064-2074, 2022 Jul

20.Yoshida T, Nagaoka T, Nagata Y, Suzuki Y, Tsutsumi T, Kuriyama S, Watanabe J, Togo S, Takahashi F, Matsushita M, Joki Y, Konishi H, Nunomura S, Izuhara K, Conway SJ, Takahashi K. Periostin-related progression of different types of experimental pulmonary hypertension: A role for M2 macrophage and FGF-2 signalling. Respirology. 27(7):529-538, 2022 Jul

21.Namkoong H, Takahashi K, Okada Y, et al. DOCK2 is involved in the host genetics and biology of severe COVID-19. Nature. 609(7928):754-760, 2022 Aug

22.Iwamura C, Hirahara K, Kiuchi M, Ikehara S, Azuma K, Shimada T, Kuriyama S, Ohki S, Yamamoto E, Inaba Y, Shiko Y, Aoki A, Kokubo K, Hirasawa R, Hishiya T, Tsuji K, Nagaoka T, Ishikawa S, Kojima A, Mito H, Hase R, Kasahara Y, Kuriyama N, Tsukamoto T, Nakamura S, Urushibara T, Kaneda S, Sakao S, Tobiume M, Suzuki Y, Tsujiwaki M, Kubo T, Hasegawa T, Nakase H, Nishida O, Takahashi K, Baba K, Iizumi Y, Okazaki T, Kimura MY, Yoshino I, Igari H, Nakajima H, Suzuki T, Hanaoka H, Nakada TA, Ikehara Y, Yokote K, Nakayama T. Elevated Myl9 reflects the Myl9-containing microthrombi in SARS-CoV-2-induced lung exudative vasculitis and predicts COVID-19 severity. Proc Natl Acad Sci U S A. 119(33):e2203437, 2022 Aug

23.Wang S Q, Takahashi K, Okada Y, et al. The whole blood transcriptional regulation landscape in 465 COVID-19 infected samples from Japan COVID-19 Task Force. Nat Commun. 13(1):4830, 2022 Aug

24.Komura M, Sato T, Yoshikawa H, Arano Nitta N, Suzuki Y, Koike K, Kodama Y, Seyama K, Takahashi K. Propylene glycol, a component of electronic cigarette liquid, damages epithelial cells in human small airways. Respir Res. 23(1):216, 2022 Aug

25.Takei S, Ai T, Yamamoto T, Igawa G, Kanno T, Tobiume M, Hiki M, Saito K, Khasawneh A, Wakita M, Misawa S, Miida T, Okuzawa A, Suzuki T, Takahashi K, Naito T, Tabe Y. Performance evaluation of the Roche Elecsys® Anti-SARS-CoV-2 immunoassays by comparison with neutralizing antibodies and clinical assessment. PLoS One. 17(9):e0274181, 2022 Sep

26.Takahashi M, Ai T, Sinozuka K, Baba Y, Igawa G, Nojiri S, Yamamoto T, Yuri M, Takei S, Saito K, Horiuchi Y, Kanno T, Tobiume M, Khasawneh A, Paran FJ, Hiki M, Wakita M, Miida T, Suzuki T, Okuzawa A, Takahashi K, Naito T, Tabe Y. Activation of SARS-CoV-2 neutralizing antibody is slower than elevation of spike-specific IgG, IgM, and nucleocapsid-specific IgG antibodies. Scientific reports. 12(1):14909, 2022 Sep

27.Heissig B, Salama Y, Iakoubov R, Vehreschil JJ, Rios R, Nogueira T, Vehreschild MJGT, Stecher M, Mori H, Lanznaster J, Adachi E, Jakob C, Tabe Y, Ruethrich M, Borgmann S, Naito T, Wille K, Valenti S, Hower M, Hattori N, Rieg S, Nagaoka T, Jensen BE, Yotsuyanagi H, Hertenstein B, Ogawa H, Wyen C, Kominami E, Roemmele C, Takahashi S, Rupp J, Takahashi K, Hanses F, Hattori K. COVID-19 Severity and Thrombo-Inflammatory Response Linked to Ethnicity. Biomedicine. 10(10): 2549, 2022 Oct

28.Gohda T, Murakoshi M, Suzuki Y, Hiki M, Naito T, Takahashi K, Tabe Y. Circulating tumor necrosis factor receptors are associated with mortality and disease severity in COVID-19 patients. PLoS One. 17(10): e0275745, 2022 Oct

29.Kurokawa K, Mitsuishi Y, Shimada N, Kawakami Y, Miura K, Miyawaki T, Asao T, Ko R, Shukuya T, Shibayama R, Nojiri S, Takahashi K. Association between the efficacy and immune-related adverse events of pembrolizumab and chemotherapy in non-small cell lung cancer patients: a retrospective study. BMC Cancer. 22(1):1047, 2022 Oct

30.Lee H, Chubachi S, Namkoong H, Asakura T, Tanaka H, Otake S, Nakagawara K, Morita A, Fukushima T, Watase M, Kusumoto T, Masaki K, Kamata H, Ishii M, Hasegawa N, Harada N, Ueda T, Ueda S, Ishiguro T, Arimura K, Saito F, Yoshiyama T, Nakano Y, Mutoh Y, Suzuki Y, Murakami K, Okada Y, Koike R, Kitagawa Y, Kimura A, Imoto S, Miyano S, Ogawa S, Kanai T, Fukunaga K; Japan COVID-19 Task Force.. Characteristics of hospitalized patients with COVID-19 during the first to fifth waves of infection: a report from the Japan COVID-19 Task Force. BMC Infect Dis. 22(1):935, 2022 Dec

31.Miyawaki T, Kenmotsu H, Doshita K, Kodama H, Nishioka N, Iida Y, Miyawaki E, Mamesaya N, Kobayashi H, Omori S, Ko R, Wakuda K, Ono A, Naito T, Murakami H, Mori K, Harada H, Endo M, Takahashi K, Takahashi T. Clinical impact of tumour burden on the efficacy of PD-1/PD-L1 inhibitors plus chemotherapy in non-small-cell lung cancer. Cancer Med. 12(2):1451-1460, 2023 Jan

32.Tomofuji Y, Suzuki K, Kishikawa T, Shojima N, Hosoe J, Inagaki K, Matsubayashi S, Ishihara H, Watada H, Ishigaki Y; BioBank Japan Project; Inohara H, Murakami Y, Matsuda K, Okada Y, Yamauchi T, Kadowaki T. Identification of serum metabolome signatures associated with retinal and renal complications of type 2 diabetes. Commun Med (Lond). 3(1):5, 2023 Jan

33.Takahashi M, Saito K, Ai T, Nojiri S, Khasawneh A, Paran FJ, Horiuchi Y, Takei S, Yamamoto T, Wakita M, Hiki M, Miida T, Naito T, Takahashi K, Tabe Y. Performance evaluation of the Ortho VITROS SARS-CoV-2 Spike-Specific Quantitative IgG test by comparison with the surrogate virus neutralizing antibody test and clinical assessment. PLoS One. 18(1):e0279779, 2023 Jan

34.Kurokawa K, Mitsuishi Y, Shimada N, Ito N, Ogiwara M, Miura K, Asao T, Ko R, Shukuya T, Shibayama R, Goto H, Takahashi K. Clinical characteristics of adrenal insufficiency induced by pembrolizumab in non-small-cell lung cancer. Thorac Cancer. 14(5):442-449, 2023 Feb

35.Watanabe J, Ihara H, Takei S, Nakamura A, Fujimoto Y, Handoh T, Kurokawa K, Arai Y, Shibayama K, Sumiyoshi I, Ochi Y, Okabe T, Misawa S, Togo S, Naito T, Tabe Y, Miida T, Takahashi K. The synergetic effect of sitafloxacin-arbekacin combination in the Mycobacterium abscessus species. Sci Rep. 13(1):2027, 2023 Feb

36.Xu S, Miura K, Shukuya T, Harada S, Fujioka M, Winardi W, Shimamura S, Kurokawa K, Sumiyoshi I, Miyawaki T, Asao T, Mitsuishi Y, Tajima K, Takahashi F, Hayashi T, Harada N, Takahashi K. Early Detection of Therapeutic Benefit from PD-1/PD-L1 Blockade in Advanced Lung Cancer by Monitoring Cachexia-Related Circulating Cytokines. Cancers (Basel). 15(4):1170, 2023 Feb

37.Jo H, Yoshida T, Yagishita S, Ohuchi M, Matsumoto Y, Shinno Y, Okuma Y, Goto Y, Horinouchi H, Yamamoto N, Takahashi K, Motoi N, Hamada A, Ohe Y. Clinical Characteristics and Pharmacokinetics Change of Long-Term Responders to Antiprogrammed Cell Death Protein 1 Inhibitor Among Patients With Advanced NSCLC. JTO Clin Res Rep. 4(4):100474, 2023 Feb

38.Kuroda Y, Kaneko T, Yoshikawa H, Uchiyama S, Nagata Y, Matsushita Y, Hiki M, Minamino T, Kazuhisa Takahashi, Daida H, Kagiyama N. Artificial intelligence-based point-of-care lung ultrasound for screening COVID-19 pneumoniae: Comparison with CT scan. PLOS ONE. https://doi.org/10.1371/journal. pone.0281127.eCollection 2023. March 16, 2023

39.Sandhu Y, Harada N, Sasano H, Harada S, Ueda S, Takeshige T, Tanabe Y, Ishimori A, Matsuno K, Abe S, Nagaoka T, Ito J, Chiba A, Akiba H, Atsuta R, Izuhara K, Miyake S, Takahashi K. Pretreatment Frequency of Circulating Th17 Cells and FeNO Levels Predicted the Real-World Response after 1 Year of Benralizumab Treatment in Patients with Severe Asthma. Biomolecules. 13(3): 538, 2023 Mar.　

40.Sekimoto Y, Sekiya M, Nojiri S, Hayakawa E, Masui Y, Tajima M, Nishino K, Nishizaki Y, Takahashi K. IFN-l3 and CCL17 as predictors of disease progression in patients with mild to moderate COVID-19: A cohort study in a real-world setting. Respir Investig. 61(2):153-156, 2023 Mar

41.Miyamoto A, Michimae H, Nakahara Y, Akagawa S, Nakagawa K, Minegishi Y, Ogura T, Hontsu S, Date H, Takahashi K, Homma S, Kishi K; Investigators Group for Lung Cancer and IIP. Chemotherapy versus best supportive care in advanced lung cancer and idiopathic interstitial pneumonias: A retrospective multi-centre cohort study. Respir Investig. 61(2):284-295, 2023 Mar

42.Kanamori R, Yan Y, Ito K, Fukuda H, Hori S, Yamamoto T, Igawa G, Saito K, Horiuchi Y, Nojiri S, Nishizaki Y, Tabe Y, Takahashi K, Naito T. Increased SARS-CoV-2 seroprevalence and spread of infection without awareness among healthcare workers through 2020-2022 in a Japanese medical center. Sci Rep. 13(1):4941, 2023 Mar

43.Nishioki T, Koyama R, Okubo H, Fukuo Y, Takasaki Y, Yae T, Banno T, Kenji K, Takahashi K, Shiina S, Ikejima K. Endobronchial Watanabe Spigot Placement for Hepatic Abscess and Bronchobiliary Fistula Following Radiofrequency Ablation for Hepatocellular Carcinoma. Intern Med, 62(7): 999-1004, 2023 Apr

44.Kanamori K, Suina K, Shukuya T, Takahashi F, Hayashi T, Hara K, Saito T, Mitsuishi Y, Shimamura SS, Winardi W, Tajima K, Ko R, Mimori T, Asao T, Itoh M, Kawaji H, Suehara Y, Takamochi K, Suzuki K, Takahashi K. CALML5 is a novel diagnostic marker for differentiating thymic squamous cell carcinoma from type B3 thymoma. Thorac Cancer. 14(12):1089-1097, 2023 Apr

45.Edahiro R, Shirai Y, Takeshima Y, Sakakibara S, Yamaguchi Y, Murakami T, Morita T, Kato Y, Liu YC, Motooka D, Naito Y, Takuwa A, Sugihara F, Tanaka K, Wing JB, Sonehara K, Tomofuji Y; Japan COVID-19 Task Force; Namkoong H, Tanaka H, Lee H, Fukunaga K, Hirata H, Takeda Y, Okuzaki D, Kumanogoh A, Okada Y. Single-cell analyses and host genetics highlight the role of innate immune cells in COVID-19 severity. Nat Genet. 55(5):753-767, 2023 May

46.Handa T, Hayashi T, Ura A, Watanabe I, Takamochi K, Onagi H, Kishi M, Matsumoto N, Tajima K, Kishikawa S, Saito T, Takahashi K, Suzuki K, Yao T. Comparison of ASCL1, NEUROD1, and POU2F3 expression in surgically resected specimens, paired tissue microarrays, and lymph node metastases in small cell lung carcinoma. Histopathology. 82(6):860-869, 2023 May

47.Saito R, Sugawara S, Ko R, Azuma K, Morita R, Maemondo M, Oizumi S, Takahashi K, Kagamu H, Tsubata Y, Seike M, Kikuchi T, Okamoto I, Satoshi M, Asahina H, Tanaka K, Sugio K, Kobayashi K. Phase 2 study of osimertinib in combination with platinum and pemetrexed in patients with previously untreated EGFR-mutated advanced non-squamous non-small cell lung cancer: The OPAL Study. Eur J Cancer. 185:83-93, 2023 May

48.Asao T, Shukuya T, Mimori T, Goto Y, Tanaka H, Takayama K, Tsubata Y, Tachihara M, Suzuki T, Kaira K, Ko R, Zenke Y, Akamatsu H, Tanizaki J, Ikeda S, Sugawara S, Mizutani H, Mori K, Takahashi K. Study Design and Rationale for Marble Study: A Phase II Trial of Atezolizumab (MPDL3280A) Plus Carboplatin and Paclitaxel in Patients With Advanced or Recurrent Thymic Carcinoma (JTD2101). Clin Lung Cancer. 19:S1525-7304(23)00099-2, 2023 May, Online ahead of print.

49.Komura M, Sato T, Suzuki Y, Yoshikawa H, Nitta NA, Hayashi M, Kuwasaki E, Horikoshi K, Nishioki T, Mori M, Kodama Y, Sasaki S, Takahashi K. Blood Eosinophil Count as a Predictive Biomarker of Chronic Obstructive Pulmonary Disease Exacerbation in a Real-World Setting. Can Respir J. 2023:3302405, 2023 May

50.Omori M, Minegishi Y, Uruga H, Fukuizumi A, Isobe K, Izumi S, Koyama R, Bando M, Sugiyama H, Takahashi K, Gemma A, Homma S, Sugiyama Y, Kishi K. Carboplatin and weekly paclitaxel in combination with bevacizumab for the treatment of advanced non-small cell lung cancer complicated by idiopathic interstitial pneumonias: A feasibility study. Respir Investig. 61(5): 625-631, 2023 Jun

51.Haraguchi M, Kiyotani K, Tate T, Sakata S, Sagawa R, Takagi S, Nagayama S, Takeuchi K, Takahashi K, Katayama R. Spatiotemporal commonality of the TCR repertoire in a T-cell memory murine model and in metastatic human colorectal cancer. Cancer Immunol Immunother. doi: 10.1007/s00262-023-03473-9, 2023 Jun.

52.Shukuya T, Takahashi K, Shintani Y, Miura K, Sekine I, Takayama K, Inoue A, Okamoto I, Kiura K, Kawaguchi T, Yamamoto N, Miyaoka E, Yoshino I, Date H. Epidemiology, risk factors and impact of cachexia on patient outcome: Results from the Japanese Lung Cancer Registry Study. J Cachexia Sarcopenia Muscle. 14(3):1274-1285, 2023 Jun

53.Torasawa M, Yoshida T, Takeyasu Y, Shimoda Y, Tateishi A, Matsumoto Y, Masuda K, Shinno Y, Okuma Y, Goto Y, Horinouchi H, Yamamoto N, Takahashi K, Ohe Y. Disease progression status during initial immune checkpoint inhibitor (ICI) affects the clinical outcome of ICI retreatment in advanced non-small cell lung cancer patients. Cancer Med. 12(11):12388-12401, 2023 Jun

54.Kojima S, Koyama S, Ka M, Saito Y, Parrish EH, Endo M, Takata S, Mizukoshi M, Hikino K, Takeda A, Gelinas AF, Heaton SM, Koide R, Kamada AJ, Noguchi M, Hamada M; Biobank Japan Project Consortium; Kamatani Y, Murakawa Y, Ishigaki K, Nakamura Y, Ito K, Terao C, Momozawa Y, Parrish NF. Mobile element variation contributes to population-specific genome diversification, gene regulation and disease risk. Nat Genet. 55(6):939-951, 2023 Jun

55.Sasano H, Harada N, Harada S, Takeshige T, Sandhu Y, Tanabe Y, Ishimori A, Matsuno K, Nagaoka T, Ito J, Chiba A, Akiba H, Atsuta R, Izuhara K, Miyake S, Takahashi K. Pretreatment circulating MAIT cells, neutrophils, and periostin predicted the real-world response after 1-year mepolizumab treatment in asthmatics. Allergol Int. 17:S1323-8930(23)00050-3, 2023 Jun, Online ahead of print.

56.Omori M, Minegishi Y, Uruga H, Fukuizumi A, Isobe K, Izumi S, Koyama R, Bando M, Sugiyama H, Takahashi K, Gemma A, Homma S, Sugiyama Y, Kishi K. Carboplatin and weekly paclitaxel in combination with bevacizumab for the treatment of advanced non-small cell lung cancer complicated by idiopathic interstitial pneumonias: A feasibility study. Respir Investig. 61(5):625-631, 2023 Jul, Online ahead of print.

57.Haraguchi M, Kiyotani K, Tate T, Sakata S, Sagawa R, Takagi S, Nagayama S, Takeuchi K, Takahashi K, Katayama R. Spatiotemporal commonality of the TCR repertoire in a T-cell memory murine model and in metastatic human colorectal cancer. Cancer Immunol Immunother. 72(9):2971-2989, 2023 Sep

58.Jin B, Oyama R, Tabe Y, Tsuchiya K, Hando T, Wakita M, Yan Y, Saita M, Takei S, Horiuchi Y, Miida T, Naito T, Takahashi K, Ogawa H. Investigation of the individual genetic evolution of SARS-CoV-2 in a small cluster during the rapid spread of the BF.5 lineage in Tokyo, Japan. Front Microbiol. 14:1229234, 2023 Sep

59.Takahashi T, Ai T, Saito K, Nojiri S, Takahashi M, Igawa G, Yamamoto T, Khasawneh A, Paran FJ, Takei S, Horiuchi Y, Kanno T, Tobiume M, Hiki M, Wakita M, Miida T, Okuzawa A, Suzuki T, Takahashi K, Naito T, Tabe Y. Assessment of antibody dynamics and neutralizing activity using serological assay after SARS-CoV-2 infection and vaccination. PLoS One. 18(9):e0291670, 2023 Sep

60.Tsuboshima K, Kurihara M, Okumura G, Ohashi K, Takahashi K, Shiko Y, Ozawa Y, Seyama K. Postoperative hormonal therapies reduce the recurrence of thoracic endometriosis-related pneumothorax. Eur J Cardiothorac Surg. 2023 Sep 29:ezad331. doi: 10.1093/ejcts/ezad331. Epub ahead of print.

61.Torasawa M, Horinouchi H, Nomura S, Igawa S, Asai M, Ishii H, Wakui H, Ushio R, Asao T, Namba Y, Koyama R, Hayakawa D, Katayama I, Matsuda H, Sasaki S, Takahashi K, Hosomi Y, Naoki K, Ohe Y. Reconsidering the cutoff value for sensitive and refractory relapses in extensive-stage small cell lung cancer in the era of immunotherapy. J Thorac Oncol. 2023 Sep 23:S1556-0864(23)02256-6. doi: 10.1016/j.jtho.2023.09.1446. Epub ahead of print.